Toxic Hepatitis
-
Upload
taufan-favian -
Category
Documents
-
view
209 -
download
0
Transcript of Toxic Hepatitis
Background
Drugs are an important cause of liver injury. More than 900 drugs, toxins, and herbs have been
reported to cause liver injury, and drugs account for 20-40% of all instances of fulminant hepatic
failure. Approximately 75% of the idiosyncratic drug reactions result in liver transplantation or death.
Drug-induced hepatic injury is the most common reason cited for withdrawal of an approved drug.
Physicians must be vigilant in identifying drug-related liver injury because early detection can
decrease the severity of hepatotoxicity if the drug is discontinued. The manifestations of drug-induced
hepatotoxicity are highly variable, ranging from asymptomatic elevation of liver enzymes to
fulminant hepatic failure. Knowledge of the commonly implicated agents and a high index of
suspicion are essential in diagnosis.2
Manifestations of Liver Dysfunction
Whether a result of hepatocyte dysfunction or portal-to-systemic shunting, prominent features of liver
disease are manifestations of failure of normal functions. An understanding of these mechanisms
offers insight into the probable causes of illness in a patient with acute or chronic liver disease.
Diminished Energy Generation & Substrate Interconversion
A first category of altered liver function involves the intermediary metabolism of carbohydrates, fats,
and proteins.
Carbohydrate Metabolism
Severe liver disease can result in either hypo- or hyperglycemia. Hypoglycemia results largely from a
decrease in functional hepatocyte mass, whereas hyperglycemia is a result of portal-to-systemic
shunting, which decreases the efficiency of postprandial extraction of glucose from portal blood by
hepatocytes, thus elevating systemic blood glucose concentration.
Lipid Metabolism
Disturbance of lipid metabolism in the liver can result in syndromes of fat accumulation within the
liver early in the course of liver injury. Perhaps this is because the complex steps in assembly of
lipoprotein particles for export of cholesterol and triglycerides from the liver are more sensitive to
1
disruption than the pathways of lipid synthesis. Such disruption results in a buildup of fat that cannot
be exported in the form of VLDL.
In certain chronic liver diseases such as primary biliary cirrhosis, bile flow decreases as a result of
destruction of bile ducts. The decrease in bile flow results in decreased lipid clearance via bile, with
consequent hyperlipidemia. These patients often develop subcutaneous accumulations of cholesterol
termed xanthomas.
Protein Metabolism
Any disturbance of protein metabolism in the liver can result in a syndrome of altered mental status
and confusion known as hepatic encephalopathy. As with carbohydrate metabolism, altered protein
metabolism can result from either hepatocyte failure or portal-to-systemic shunting, with the net effect
of elevation of blood concentrations of centrally acting toxins, including ammonia generated by
amino acid metabolism.7
Table 1. Categories of Liver Disease by Presentation.4
Cholestasis
Reactions to certain classes of drugs (including anabolic steroids, oral contraceptives, phenothiazines, erythromycins, oral hypoglycemic and antithyroid drugs)
Direct causes (intrahepatic biliary atresia, cholangiocarcinoma, viral hepatitis, alcoholic hepatitis, primary biliary cirrhosis, pericholangitis)
Secondary causes (postoperative, endotoxins, total parenteral nutrition, sickle cell crisis, hypophysectomy, some porphyrias)
Acute hepatitis
Viral and bacterial, including hepatitis viruses A, B, C, D, and E, herpes simplex virus, cytomegalovirus, Epstein-Barr virus, yellow fever virus, brucella, leptospira
Reactions to certain classes of drugs (anesthetics such as halothane, anticonvulsants such as phenytoin, antihypertensives such as methyldopa, chemotherapeutic agents such as isoniazid, and thiazide diuretics such as hydrochlorothiazide)
Poisons (such as ethanol); reactions to drugs
Fulminant hepatic failure
Infections (with hepatitis viruses A, B, and D, yellow fever virus, cytomegalovirus; herpes simplex
2
virus, and Coxiella burnetii)
Poisons and toxins, chemicals, herbal remedies, and drugs (Amanita phalloides toxin, phosphorus, ethanol; solvents, including carbon tetrachloride and dimethylformamide; anesthetics, including halothane; analgesics, including acetaminophen; antimicrobials, including tetracycline and isoniazid; and other drugs, including methyldopa, monoamine oxidase inhibitors, valproate, methylenedioxymethamphetamine [Ecstasy])
Ischemia and hypoxia (vascular occlusion, circulatory failure, heat stroke, gram-negative sepsis with shock, congestive heart failure, pericardial tamponade, Budd-Chiari syndrome)
Miscellaneous metabolic anomalies (acute fatty liver of pregnancy, Reye's syndrome, Wilson's disease, galactosemia, tyrosinemia)
Chronic hepatitis
Viral hepatitis (types B, C, and D)
Primary autoimmune disorders (idiopathic autoimmune chronic hepatitis, primary biliary cirrhosis, and sclerosing cholangitis)
Therapeutic drug–induced (methyldopa, nitrofurantoin, oxyphenisatin-containing laxatives)
Genetic diseases (Wilson's disease, -antiprotease deficiency)
Infiltrative disorders (sarcoidosis, amyloidosis, hemochromatosis)
Cirrhosis
Infectious (viral hepatitis types B, C, and D and toxoplasmosis)
Genetic diseases (Wilson's disease, hemochromatosis, -antiprotease deficiency, glycogen storage diseases, Fanconi's syndrome, cystic fibrosis)
Drugs and poisons (eg, methotrexate, alcohol)
Miscellaneous (sarcoidosis, graft-versus-host disease, inflammatory bowel disease, cystic fibrosis, jejunoileal bypass, diabetes mellitus)
Focal or extrinsic diseases with variable manifestations in the liver
Vascular (hepatic vein thrombosis, occlusion by parasites such as echinococcus or schistosoma)
Biliary (duct obstruction due to stones or tumor or bacterial infection)
Infectious (systemic sepsis; bacterial, fungal, or parasitic abscesses)
Granulomatous diseases (sarcoidosis, tuberculosis)Infiltrative diseases (hemochromatosis, amyloidosis, Gaucher's disease and other lysosomal storage diseases, lymphoma)
3
Infiltrative diseases (hemochromatosis, amyloidosis, Gaucher's disease and other lysosomal storage diseases, lymphoma)
Loss of Solubilization & Storage Functions
Disordered Bile Secretion
The clinical significance of bile synthesis can be seen in the prominence of cholestasis—failure to
secrete bile—in many forms of liver disease. Cholestasis can occur as a result of extrahepatic
obstruction (eg, from a gallstone in the common bile duct) or selective dysfunction of the bile
synthetic and secretory machinery within the hepatocytes themselves (eg, from a reaction to certain
drugs). The mechanisms responsible for cholestatic drug reactions are not well understood.
Regardless of the mechanism, however, the clinical consequences of severe cholestasis may be
profound: A failure to secrete bile results in a failure to solubilize substances such as dietary lipids
and fat-soluble vitamins, resulting in malabsorption and deficiency states, respectively. Retained bile
salts are also cytotoxic, but in the setting of cholestasis hepatocytes adapt to decrease uptake of bile
salts by downregulating Ntcp while maintaining bile salt excretion. As a result, hepatic necrosis is
minimized in predominantly cholestatic syndromes, with the typical laboratory findings of minimally
elevated levels of AST and ALT in the presence of marked jaundice and high levels of bilirubin.
However, prolonged exposure to bile salts in chronic cholestatic diseases such as primary biliary
cirrhosis leads to portal tract cytotoxic injury and inflammation, leading eventually to fibrosis and
cirrhosis.
The solubilization function of bile works both to excrete and to absorb substances. Thus, in
cholestasis, endogenous substances that are normally excreted via the biliary tract can accumulate to
high levels. One such substance is bilirubin, a product of heme degradation. The buildup of bilirubin
results in jaundice (icterus), which is a yellow discoloration of the scleras and skin. In the adult, the
most significant feature of jaundice is that it serves as a readily monitored index of cholestasis, which
may occur alone or with other abnormalities in hepatocyte function (ie, as part of the presentation of
acute hepatitis). In the neonate, however, elevated bilirubin concentrations can be toxic to the
developing nervous system, producing a syndrome termed kernicterus.
Similarly, cholesterol is normally excreted either by conversion into bile acids or by forming
complexes, termed micelles, with preexisting (recycled) bile acids. In cholestasis, the resultant
buildup of bile acids can lead to their deposition in the skin. This is believed to cause intense itching,
4
or pruritus. Data suggest that in at least some patients cholestasis results in altered levels of
endogenous opioids. Altered endogenous opioid-mediated neurotransmission may be responsible for
pruritus instead of skin deposition of bile acids. Disorders of bile production are a basis for the
formation of cholesterol gallstones. Nevertheless, as mentioned, other hepatocyte functions are often
relatively well preserved in the face of significant cholestasis.
Hemolysis causes an unconjugated hyperbilirubinemia because the hepatic capacity to take up and
conjugate bilirubin is exceeded. Gilbert's syndrome reflects a genetic defect in bilirubin conjugation.
Thus, the findings in blood and urine are different from what is observed in hemolytic jaundice even
though the pathway of bilirubin metabolism is backed up at a similar initial point. Extrahepatic biliary
tract obstruction presents the other extreme, in which the actual pathway of bile formation is entirely
intact, at least initially. In obstruction, the bilirubin level in the urine is high because the backed-up
metabolite is conjugated and hence much more water soluble than unconjugated bilirubin, which
accumulates in hemolysis. Most forms of jaundice that result from liver dysfunction caused by
hepatocellular damage reflect variable degrees of overlap between unconjugated and conjugated
hyperbilirubinemia.
Impaired Drug Detoxification
Two features of the mechanisms of drug detoxification are of particular clinical importance. One is
the phenomenon of enzyme induction. It is observed that the presence in the bloodstream of any of
the large class of drugs inactivated by phase I enzymes increases the amount and activity of these
enzymes in the liver. This property of enzyme induction makes physiologic sense (as a response to the
body's need for increased biotransformation) but can have undesired effects as well: A patient who
chronically consumes large amounts of a substance that is metabolized by phase I enzymes (eg,
ethanol) will induce high levels of these enzymes and thus speed up the metabolism of other
substances metabolized by the same detoxifying enzymes (eg, antiseizure or anticoagulant
medications, resulting in subtherapeutic blood levels of the drugs).
A second clinically important phenomenon in drug metabolism is that phase I reactions often convert
relatively benign compounds into more reactive and hence more toxic ones. Normally, this heightened
reactivity of phase I reaction products serves to facilitate phase II reactions, making detoxification
more efficient. However, under certain conditions when phase II reactions are impaired (eg, during
glutathione deficiency from inadequate nutrition), continued phase I enzyme activity can cause
increased liver injury. This is because the products of many phase I reactions, in the absence of
glutathione, react with and damage cellular components. Such damage rapidly kills the hepatocyte.
5
Thus, the combined effects of certain common conditions can make the individual abnormally
sensitive to the toxic effects of drugs. For example, the combination of induced phase I activity (eg,
caused by alcoholism) with low phase II activity (eg, caused by low glutathione levels from
nutritional deprivation) can result in heightened generation of reactive intermediates with an
inadequate capacity to conjugate and detoxify them. A classic example of this phenomenon is
acetaminophen toxicity. As little as 2.5 g of acetaminophen can produce significant liver damage in
such susceptible individuals, whereas normal individuals have the capacity to detoxify 10 g/d or more.
Lipoprotein Dynamics and Dyslipidemias
The liver's role in lipid metabolism is illustrated by the genetic defect causing familial
hypercholesterolemia. Lack of a functional LDL receptor in such cases renders the liver unable to
clear LDL cholesterol from the bloodstream, resulting in markedly elevated serum cholesterol and
accelerated atherosclerosis and coronary artery disease. Heterozygotes with one normal LDL receptor
allele can be treated with drugs (eg, HMG-CoA reductase inhibitors) that inhibit endogenous
cholesterol synthesis and thus upregulate LDL receptor levels. However, there is no effective drug
therapy for homozygotes because they have no normal LDL receptors. Hepatic transplantation is
effective therapy for homozygous familial hypercholesterolemia because it provides a genetically
different liver with normal LDL receptors.
In acquired liver diseases, the serum cholesterol is elevated in biliary tract obstruction as a result of
blockage of cholesterol excretion in bile, and it is diminished in severe alcoholic cirrhosis, in which
fat malabsorption prevents cholesterol intake.
Altered Hepatic Binding and Storage Functions
Liver disease influences the liver's ability to store various substances. As a result, patients with liver
disease are at high risk for certain deficiency states such as folic acid and vitamin B12 deficiency.
Because these vitamins are needed for DNA synthesis, their deficiency results in macrocytic anemia
(low red blood cell count with large red cells reflecting abnormal nuclear maturation), a common
finding in patients with liver disease.
Diminished Synthesis & Secretion of Plasma Proteins
The clinical significance of liver protein synthesis and secretion derives from the wide range of
functions carried out by these proteins. For example, because albumin is the major contributor to
plasma oncotic pressure, hypoalbuminemia as a consequence of liver disease or nutritional deficiency
6
presents with marked edema formation. Other important proteins synthesized and secreted by the liver
include clotting factors and hormone-binding proteins.
Loss of Protective & Clearance Functions
A crucial protective function of the liver is its role as a filter of blood from the GI tract, by which
various substances are removed from portal blood before it reenters the systemic circulation.
Clearance of Bacteria and Endotoxin
Clearance of bacteria by Kupffer cells of the liver is the final line of defense in keeping gut-derived
bacteria out of the systemic circulation. Loss of this capacity in liver disease as a result of portal-to-
systemic shunting may help to explain why, in patients with severe liver disease, infections can
rapidly become systemic and result in sepsis.
Altered Ammonia Metabolism
Impairment of the liver's ability to detoxify ammonia to urea leads to hepatic encephalopathy,
manifested as an altered mental status. This may be an early manifestation of acute fulminant hepatitis
with massive hepatocellular dysfunction even before the development of maximal hepatocellular
necrosis. It can be a final step in progressive chronic liver disease with diminished hepatocyte
functional capacity. Most often it is a consequence of an increased ammonia load in a patient with
marginal liver function or significant portal-to-systemic shunting. Thus, encephalopathy may occur as
a first sign of renewed GI bleeding (as a result of increased production of ammonia and other products
caused by breakdown of blood protein by GI tract microbes) or may simply be due to increased
protein intake (eg, a cheeseburger eaten by a patient with cirrhosis). Finally, the development of
sepsis in these patients results in increased endogenous protein catabolism and, therefore, elevated
ammonia production in the face of a decreased capacity for ammonia detoxification because of the
liver disease. Thus, the development of encephalopathy in a patient with chronic liver disease calls for
investigation of possible acute GI bleeding as well as potentially catastrophic infection. Pending the
outcome of diagnostic studies (eg, serial hematocrit measurements and cultures of blood, urine, and
ascitic fluid), therapy is designed to improve mental status by diminishing the absorption of ammonia
and other noxious substances from the GI tract. When the patient is given the nonabsorbable
carbohydrate lactulose, whose metabolism by microbes creates an acidic environment, ammonia is
trapped as the charged NH4+ species in the gut lumen and excreted by the resultant osmotic diarrhea.
Thus, this toxin is prevented from ever entering the portal circulation, and the patient's mental status
gradually improves. Lactulose also selects for a gut bacterial flora that produces less ammonia.
7
Furthermore, the resulting elevated blood ammonia and other nitrogen-containing compounds can
upregulate peripheral receptors for endogenous benzodiazepine-like products. These effects may
contribute to altered systemic hemodynamics in liver disease.
Altered Hormone Clearance in Liver Disease
Normally, the liver removes from the bloodstream the fraction of steroid hormones not bound to
steroid hormone-binding globulin. On uptake by hepatocytes, these steroids are oxidized, conjugated,
and excreted into bile, where a fraction undergoes enterohepatic circulation. In liver disease
accompanied by significant portal-to-systemic shunting, steroid hormone clearance is diminished,
extraction of the enterohepatic circulated fraction is impaired, and enzymatic conversion of androgens
to estrogens (peripheral aromatization) is increased. The net effect is an elevation of blood estrogens,
which in turn alters hepatocyte protein synthesis and secretion and microsomal P450 activity.
Synthesis of some hepatic proteins increases, whereas synthesis of others is diminished. P450 activity
increases as the liver attempts to partially compensate for the higher blood estrogen levels by
increased metabolism. Thus, male patients with liver disease display both gonadal and pituitary
suppression as well as feminization.
Sodium & Water Balance
Patients with liver disease often display renal abnormalities and complications, most commonly
sodium retention and difficulty excreting water. An intrinsic renal lesion is apparently not involved,
because the kidneys of patients with liver disease typically function normally when transplanted into
patients whose liver is normal. Instead, renal abnormalities associated with liver disease are
functional, occurring because liver disease induces altered intravascular pressures and perhaps
because of elevated nitric oxide levels or loss of as yet poorly understood factors secreted from the
liver or the endothelium. By whatever homeostatic mechanisms, intravascular volume is perceived as
being inadequate when it is actually only maldistributed. Renal mechanisms of salt and water
retention are then stimulated to correct what has been sensed as volume depletion. 4
Jaundice
Essentials of Diagnosis
8
Results from accumulation of bilirubin in the body tissues; cause may be hepatic or
nonhepatic.
Hyperbilirubinemia may be due to abnormalities in the formation, transport, metabolism, and
excretion of bilirubin.
Total serum bilirubin is normally 0.2–1.2 mg/dL; jaundice may not be recognizable until
levels are about 3 mg/dL.
Evaluation of obstructive jaundice begins with ultrasonography and is usually followed by
cholangiography.
General Considerations
Jaundice (icterus) results from the accumulation of bilirubin—a product of heme metabolism—in the
body tissues (see photograph). Hyperbilirubinemia may be due to abnormalities in the formation,
transport, metabolism, and excretion of bilirubin. Total serum bilirubin is normally 0.2–1.2 mg/dL
(mean levels are higher in men than women and higher in whites and hispanics than blacks), and
jaundice may not be recognizable until levels are about 3 mg/dL.
Table 2. Classification of jaundice.7
Type of Hyperbilirubinemia Location and Cause
Unconjugated hyperbilirubinemia (predominant indirect-reacting bilirubin)
Increased bilirubin production (eg, hemolytic anemias, hemolytic reactions, hematoma, pulmonary infarction)
Impaired bilirubin uptake and storage (eg, posthepatitis hyperbilirubinemia, Gilbert syndrome, Crigler–Najjar syndrome, drug reactions)
Conjugated hyperbilirubinemia (predominant direct-reacting bilirubin)
HEREDITARY CHOLESTATIC SYNDROMES
Faulty excretion of bilirubin conjugates (eg, Dubin-Johnson syndrome, Rotor syndrome) or mutation in genes coding for bile salt transport proteins (eg, progressive familial intrahepatic cholestasis syndromes, benign recurrent intrahepatic cholestasis, and some cases of intrahepatic cholestasis of pregnancy)
HEPATOCELLULAR DYSFUNCTION
9
Type of Hyperbilirubinemia Location and Cause
Biliary epithelial damage (eg, hepatitis, hepatic cirrhosis)
Intrahepatic cholestasis (eg, certain drugs, biliary cirrhosis, sepsis, postoperative jaundice)
Hepatocellular damage or intrahepatic cholestasis resulting from miscellaneous causes (eg, spirochetal infections, infectious mononucleosis, cholangitis, sarcoidosis, lymphomas, industrial toxins)
BILIARY OBSTRUCTION
Choledocholithiasis, biliary atresia, carcinoma of biliary duct, sclerosing cholangitis, choledochal cyst, external pressure on common duct, pancreatitis, pancreatic neoplasms
Nature of Defect
Type of Hyperbilirubinemia
Clinical and Pathologic Characteristics
Gilbert syndrome
Reduced activity of glucuronyl transferase
Unconjugated (indirect) bilirubin
Benign, asymptomatic hereditary jaundice. Hyperbilirubinemia increased by 24- to 36-hour fast. No treatment required. Prognosis excellent.
Dubin–Johnson syndrome
Faulty excretory function of hepatocytes
Conjugated (direct) bilirubin
Benign, asymptomatic hereditary jaundice. Gallbladder does not visualize on oral cholecystography. Liver darkly pigmented on gross examination. Biopsy shows centrilobular brown pigment. Prognosis excellent.
Rotor syndrome
Similar to Dubin–Johnson syndrome, but liver is not pigmented and the gallbladder is visualized on oral cholecystography. Prognosis excellent.
Benign recurrent intrahepatic
Cholestasis, often on a
Unconjugated plus conjugated (total)
Episodic attacks of jaundice, itching, and malaise. Onset in early life and may persist for a lifetime. Alkaline phosphatase
10
Table 3. Hyperbilirubinemic disorders.7
Nature of Defect
Type of Hyperbilirubinemia
Clinical and Pathologic Characteristics
cholestasis
familial basis bilirubin increased. Cholestasis found on liver biopsy. (Biopsy is normal during remission.) Prognosis excellent.
Intrahepatic cholestasis of pregnancy
Benign cholestatic jaundice, usually occurring in the third trimester of pregnancy. Itching, gastrointestinal symptoms, and abnormal liver excretory function tests. Cholestasis noted on liver biopsy. Prognosis excellent, but recurrence with subsequent pregnancies or use of birth control pills is characteristic.
Clinical Findings
Unconjugated Hyperbilirubinemia
Stool and urine color are normal, and there is mild jaundice and indirect (unconjugated)
hyperbilirubinemia with no bilirubin in the urine. Splenomegaly occurs in hemolytic disorders except
in sickle cell anemia.
Conjugated Hyperbilirubinemia
Hereditary cholestatic syndromes or intrahepatic cholestasis
The patient may be asymptomatic; cholestasis is often accompanied by pruritus, light-colored stools,
and jaundice.
Table 4. Liver biochemical tests: Normal values and changes in two types of jaundice. 4
Tests Normal Values Hepatocellular Jaundice Uncomplicated Obstructive Jaundice
Bilirubin
Direct 0.1–0.3 mg/dL Increased Increased
Indirect 0.2–0.7 mg/dL Increased Increased
11
Tests Normal Values Hepatocellular Jaundice Uncomplicated Obstructive Jaundice
Urine bilirubin None Increased Increased
Serum albumin/total protein
Albumin, 3.5–5.5 g/dL
Albumin decreased
Total protein, 6.5–8.4 g/dL
Unchanged
Alkaline phosphatase
30–115 units/L Increased (+) Increased (++++)
Prothrombin time
INR1 of 1.0–1.4. After vitamin K, 10% increase in 24 hours
Prolonged if damage severe and does not respond to parenteral vitamin K
Prolonged if obstruction marked, but responds to parenteral vitamin K
ALT, AST
ALT, 5–35 units/L; AST, 5–40 units/L
Increased in hepatocellular damage, viral hepatitis
Minimally increased
Table 5. Causes of serum aminotransferase elevations. 4
Mild Elevations (< 5 x normal)
Severe Elevations (> 15 x normal)
Hepatic: ALT-predominant Acute viral hepatitis (A-E, herpes)
Chronic hepatitis B, C, D Medications/toxins
Acute viral hepatitis (A-E, EBV, CMV) Ischemic hepatitis
Steatosis/steatohepatitis Autoimmune hepatitis
Hemochromatosis Wilson disease
Medications/toxins Acute bile duct obstruction
Autoimmune hepatitis Acute Budd–Chiari syndrome
Antitrypsin deficiency Hepatic artery ligation
Wilson disease
Celiac disease
Hepatic: AST-predominant
12
Mild Elevations (< 5 x normal)
Severe Elevations (> 15 x normal)
Alcohol-related liver injury (AST:ALT > 2:1)
Cirrhosis
Nonhepatic
Strenuous exercise
Hemolysis
Myopathy
Thyroid disease
Macro-AST
Imaging
Demonstration of dilated bile ducts by ultrasonography (see ultrasound) or CT scan indicates biliary
obstruction (90–95% sensitivity). Ultrasonography, CT scan (see CT scan), and MRI may also
demonstrate hepatomegaly, intrahepatic tumors, and portal hypertension. Multiphasic helical or
multislice CT, CT arterial portography, in which imaging follows intravenous contrast infusion via a
catheter placed in the superior mesenteric artery, MRI with use of gadolinium or ferumoxides as
contrast agents, and intraoperative ultrasonography are the most sensitive techniques for detection of
individual small hepatic lesions in patients eligible for resection of metastases. Use of color Doppler
ultrasound or contrast agents that produce microbubbles increases the sensitivity of transcutaneous
ultrasound for detecting small neoplasms. MRI is the most accurate technique for identifying isolated
liver lesions such as hemangiomas, focal nodular hyperplasia, or focal fatty infiltration and for
detecting hepatic iron overload. Dynamic gadolinium-enhanced MRI and administration of
superparamagnetic iron oxide show promise in visualizing hepatic fibrosis.
Alcoholic Liver Disease
Essentials of Diagnosis
13
Chronic alcohol intake usually exceeds 80 g/d in men and 30–40 g/d in women with alcoholic
hepatitis or cirrhosis.
Fatty liver is often asymptomatic.
Fever, right upper quadrant pain, tender hepatomegaly, and jaundice characterize alcoholic
hepatitis, but the patient may be asymptomatic.
AST is usually elevated but rarely above 300 units/L; AST is greater than ALT, usually by a
factor of 2 or more.
Alcoholic hepatitis is often reversible but it is the most common precursor of cirrhosis in the
United States.7
General Considerations
Excessive alcohol intake can lead to fatty liver, hepatitis, and cirrhosis. Alcoholic hepatitis is
characterized by acute or chronic inflammation and parenchymal necrosis of the liver induced by
alcohol. Alcoholic hepatitis is often a reversible disease, is the most common precursor of cirrhosis in
the United States, and is associated with four to five times the number of hospitalizations and deaths
as hepatitis C, which is the second most common cause of cirrhosis.
The frequency of alcoholic cirrhosis is estimated to be 10–15% among persons who consume over 50
g of alcohol (4 oz of 100-proof whiskey, 15 oz of wine, or four 12-oz cans of beer) daily for over 10
years (although the risk of cirrhosis may be lower for wine than for a comparable intake of beer or
spirits). The risk of cirrhosis is lower (5%) in the absence of other cofactors such as chronic viral
hepatitis and obesity. Genetic factors, including polymorphisms of the genes encoding for tumor
necrosis factor and cytochrome P450 2E1, may also account for differences in susceptibility. Women
appear to be more susceptible than men, in part because of lower gastric mucosal alcohol
dehydrogenase levels. Over 80% of patients with alcoholic hepatitis have been drinking 5 years or
more before symptoms that can be attributed to liver disease develop; the longer the duration of
drinking (10–15 or more years) and the larger the alcoholic consumption, the greater the probability
of developing alcoholic hepatitis and cirrhosis. In individuals who drink alcohol excessively, the rate
of ethanol metabolism can be sufficiently high to permit the consumption of large quantities without
raising the blood alcohol level over 80 mg/dL.
Deficiencies in vitamins and calories probably contribute to the development of alcoholic hepatitis or
its progression to cirrhosis. Many adverse effects of alcohol on the liver are thought to be mediated by
tumor necrosis factor and by the oxidative metabolite acetaldehyde, which contributes to lipid
14
peroxidation and induction of an immune response following covalent binding to proteins in the
liver.4
Clinical Findings
Symptoms and Signs
The clinical presentation of alcoholic liver disease can vary from an asymptomatic hepatomegaly to a
rapidly fatal acute illness or end-stage cirrhosis. A recent period of heavy drinking, complaints of
anorexia and nausea, and the demonstration of hepatomegaly and jaundice (see photograph) strongly
suggest the diagnosis. Abdominal pain and tenderness, splenomegaly, ascites (see photograph), fever,
and encephalopathy may be present.
Laboratory Findings
In patients with steatosis, mild liver enzyme elevations may be the only laboratory abnormality.
Anemia (usually macrocytic) may be present. Leukocytosis with shift to the left is common in patients
with severe alcoholic hepatitis. Leukopenia is occasionally seen and resolves after cessation of
drinking. About 10% of patients have thrombocytopenia related to a direct toxic effect of alcohol on
megakaryocyte production or to hypersplenism.
AST is usually elevated but rarely above 300 units/L. AST is greater than ALT, usually by a factor of
2 or more. Serum alkaline phosphatase is generally elevated, but seldom more than three times the
normal value. Serum bilirubin is increased in 60–90% of patients with alcoholic hepatitis. Serum
bilirubin levels greater than 10 mg/dL and marked prolongation of the prothrombin time (6 seconds
above control) indicate severe alcoholic hepatitis with a mortality rate as high as 50%. The serum
albumin is depressed, and the globulin level is elevated in 50–75% of individuals, even in the absence
of cirrhosis. Increased transferrin saturation, hepatic iron stores, and sideroblastic anemia are found in
many alcoholic patients. Folic acid deficiency may coexist.
Liver Biopsy
Liver biopsy, if done, demonstrates macrovesicular fat and, in patients with alcoholic hepatitis,
polymorphonuclear infiltration with hepatic necrosis, Mallory bodies (alcoholic hyaline), and
perivenular and perisinusoidal fibrosis (see micrograph). Micronodular cirrhosis may be present as
well. The findings are identical to those of nonalcoholic steatohepatitis.
Other Studies
15
Imaging studies are used to exclude other diagnoses; they can detect moderate to severe hepatic
steatosis reliably but not inflammation or fibrosis. Ultrasound helps exclude biliary obstruction and
identifies subclinical ascites. CT scanning with intravenous contrast or MRI may be indicated in
selected cases to evaluate patients for collateral vessels, space-occupying lesions of the liver, or
concomitant disease of the pancreas.
Differential Diagnosis
Alcoholic hepatitis may be closely mimicked by cholecystitis and cholelithiasis and by drug toxicity.
Other causes of hepatitis or chronic liver disease may be excluded by serologic or biochemical testing,
by imaging studies, or by liver biopsy. A formula based on the AST/ALT ratio, body mass index,
mean corpuscular volume, and gender has been reported to reliably distinguish alcoholic liver disease
from nonalcoholic fatty liver disease (NAFLD).
Treatment
General Measures
Abstinence from alcohol is essential. Fatty liver is quickly reversible with abstinence. Every effort
should be made to provide sufficient amounts of carbohydrates and calories in anorectic patients to
reduce endogenous protein catabolism, promote gluconeogenesis, and prevent hypoglycemia.
Nutritional support (40 kcal/kg with 1.5–2 g/kg as protein) improves survival in patients with
malnutrition. Use of liquid formulas rich in branched-chain amino acids does not improve survival
beyond that achieved with less expensive caloric supplementation. The administration of vitamins,
particularly folic acid and thiamine, is indicated, especially when deficiencies are noted; glucose
administration increases the vitamin B1 requirement and can precipitate Wernicke–Korsakoff
syndrome if thiamine is not coadministered.
Pharmacologic Measures
Methylprednisolone, 32 mg/d orally or the equivalent for 1 month, may reduce short-term mortality in
patients with alcoholic hepatitis and either encephalopathy or a discriminant function (defined by the
patient's prothrombin time minus the control prothrombin time times 4.6 plus the total bilirubin in
mg/d is > 32). Failure of the serum bilirubin level to decline after 7 days of treatment predicts
nonresponse and poor long-term survival, as does a model that includes age, renal failure, serum
albumin, prothrombin time, serum bilirubin on admission, and serum bilirubin on day 7. No benefit
has been demonstrated in patients with concomitant gastrointestinal bleeding.
16
Pentoxifylline—an inhibitor of tumor necrosis factor—400 mg orally three times daily for 4 weeks,
may reduce 1-month mortality rates in patients with severe alcoholic hepatitis, primarily by
decreasing the risk of hepatorenal syndrome. Other experimental therapies include propylthiouracil,
oxandrolone, S-adenosyl-L-methionine, infliximab, antioxidants, and extracorporeal liver support.
Colchicine does not reduce mortality in patients with alcoholic cirrhosis.
Prognosis
Short-Term
When the prothrombin time is short enough to permit liver biopsy (< 3 seconds above control), the 1-
year mortality rate is 7%, rising to 20% if there is progressive prolongation of the prothrombin time
during hospitalization. Individuals in whom the prothrombin time prohibits liver biopsy have a 42%
mortality rate at 1 year. Other unfavorable prognostic factors are a serum bilirubin greater than 10
mg/dL, hepatic encephalopathy, azotemia, leukocytosis, lack of response to corticosteroid therapy,
and possibly little steatosis on a liver biopsy specimen and reversal of portal blood flow by Doppler
ultrasound. In addition to the discriminant function discussed above, the MELD score used for
cirrhosis (see later) and the Glasgow alcoholic hepatitis score (based on age, white blood cell count,
blood urea nitrogen, prothrombin time ratio, and bilirubin level) correlate with mortality from
alcoholic hepatitis and have higher specificities.
Long-Term
In the United States, the 3-year mortality rate of persons who recover from acute alcoholic hepatitis is
ten times greater than that of control individuals of comparable age. Histologically severe disease is
associated with continued excessive mortality rates after 3 years, whereas the death rate is not
increased after the same period in those whose liver biopsies show only mild alcoholic hepatitis.
Complications of portal hypertension (ascites, variceal bleeding, hepatorenal syndrome),
coagulopathy, and severe jaundice following recovery from acute alcoholic hepatitis also suggest a
poor long-term prognosis. Alcoholic cirrhosis is a risk factor for hepatocellular carcinoma, and the
risk is highest in carriers of the C282Y mutation for hemochromatosis or with increased hepatic iron.
The most important prognostic consideration is continued excessive drinking. A 6-month period of
abstinence is generally required before liver transplantation is considered, although this requirement
has been questioned.4
17
Drug- & Toxin-Induced Liver Disease
Most cases of drug-induced liver disease present as acute hepatitis, although some present as
cholestasis or other patterns. The incidence of drug-induced hepatitis has been rising; acetaminophen
is now the most common cause of fulminant hepatitis in the United States and the United Kingdom.
Hepatic toxins can be further subdivided into those for which hepatic toxicity is predictable and dose
dependent for most individuals (eg, acetaminophen) and those that cause unpredictable (idiosyncratic)
reactions without relationship to dose. Idiosyncratic reactions to drugs may be due to genetic
predisposition in susceptible individuals to certain pathways of drug metabolism that generate toxic
intermediates. Prominent examples of drugs causing acute liver failure that have been withdrawn from
the U.S. market include bromfenac, a nonsteroidal anti-inflammatory drug (NSAID), and troglitazone
sulfate, a thiazolidinedione used as an insulin-sensitizing agent in diabetes mellitus. Other
thiazolidinediones such as rosiglitazone and pioglitazone do not seem to have the same complication,
although routine testing of transaminases has been recommended for those taking the drugs. HMG-
CoA reductase inhibitors such as atorvastatin, lovastatin, and others are associated with elevated
levels of transaminases in less than 3% of patients and with few cases of acute liver failure.4
Essentials of Diagnosis
Drug-induced liver disease can mimic viral hepatitis, biliary tract obstruction, or other types
of liver disease.
Clinicians must inquire about the use of many widely used therapeutic agents, including over-
the-counter "natural" and "herbal" products, in any patient with liver disease.1
General Considerations
Many therapeutic agents may cause hepatic injury. The medications most commonly implicated are
nonsteroidal anti-inflammatory drugs and antibiotics because of their widespread use. Drug-induced
liver disease can mimic viral hepatitis, biliary tract obstruction, or other types of liver disease. In any
patient with liver disease, the clinician must inquire carefully about the use of potentially hepatotoxic
drugs or exposure to hepatotoxins, including over-the-counter "natural" and herbal products. In some
cases, coadministration of a second agent may increase the toxicity of the first (eg, isoniazid and
rifampin, acetaminophen and alcohol). Drug toxicity may be categorized on the basis of pathogenesis
or histologic appearance.
18
Direct Hepatotoxic Group
The liver lesion caused by this group of drugs is characterized by (1) dose-related severity, (2) a latent
period following exposure, and (3) susceptibility in all individuals. Examples include acetaminophen
(toxicity is enhanced by fasting and chronic alcohol use because of depletion of glutathione and
induction of cytochrome P450 2E1), alcohol, carbon tetrachloride, chloroform, heavy metals,
mercaptopurine, niacin, plant alkaloids, phosphorus, tetracyclines, tipranavir, valproic acid, and
vitamin A. Statins, like all cholesterol-lowering agents, may cause serum aminotransferase elevations
but rarely cause true hepatitis and are no longer considered contraindicated in patients with liver
disease.
Idiosyncratic Reactions
Except for acetaminophen, most severe hepatotoxicity is idiosyncratic. Reactions of this type are (1)
sporadic, (2) not related to dose, and (3) occasionally associated with features suggesting an allergic
reaction, such as fever and eosinophilia, which may be associated with a favorable outcome. In some
patients, toxicity results directly from a metabolite that is produced only in certain individuals on a
genetic basis. Toxicity may be observed only on post-marketing surveillance and not during
preclinical trials. Examples include amiodarone, aspirin, carbamazepine, chloramphenicol, diclofenac,
disulfiram, duloxetine, ezetimibe, flutamide, halothane, isoniazid, ketoconazole, lamotrigine,
methyldopa, nevirapine, oxacillin, phenytoin, pyrazinamide, quinidine, streptomycin, rofecoxib and
troglitazone (both withdrawn from the market in the United States), and less commonly other
thiazolidinediones, and perhaps tacrine.
Table 6. Principal Alterations of Hepatic Morphology Produced by Some Commonly Used Drugs and Chemicals.7
Principal Morphologic Change
Class of Agent Example
Cholestasis Anabolic steroid Methyltestosterone
Antithyroid Methimazole
Antibiotic Erythromycin estolate
Nitrofurantoin
Oral contraceptive Norethynodrel with mestranol
19
Principal Morphologic Change
Class of Agent Example
Oral hypoglycemic Chlorpropamide
Tranquilizer Chlorpromazine\
Oncotherapeutic Anabolic steroids
Busulfan
Tamoxifen
Immunosuppressive Cyclosporine
Anticonvulsant Carbamazepine
Calcium channel blocker
Diltiazem
Nifedipine
Verapamil
Angiotensin-converting enzyme inhibitor
Captopril
Enalapril
Antidepressant Trazadone
Fatty liver Antibiotic Tetracycline
Anticonvulsant Sodium valproate
Antiarrhythmic Amiodarone
Oncotherapeutic Asparaginase
Methotrexate
Hepatitis Anesthetic Halothane
Anticonvulsant Phenytoin
Carbamazepine
Lamotrigine
20
Principal Morphologic Change
Class of Agent Example
Felbamate
Antihypertensive Methyldopa
Captopril
Enalapril
Antibiotic Isoniazid
Rifampin
Nitrofurantoin
Diuretic Chlorothiazide
Laxative Oxyphenisatin
Antidepressant Amitriptyline
Imipramine
Nefazodone
Venlafaxine
Anti-inflammatory Ibuprofen
Indomethacin
Antifungal Ketoconazole
Fluconazole
Antiviral Ritonavir
Efavirenz
Nevirapine
Zidovudine
Dideoxyinosine
Calcium channel Nifedipine
21
Principal Morphologic Change
Class of Agent Example
blocker
Verapamil
Diltiazem
Leukotriene receptor antagonist
Zafirlukast
Antipsychotic Clozapine
Mixed hepatitis and cholestasis
Immunosuppressive Azathioprine
Lipid lowering Nicotinic acid
Lovastatin, atorvastatin, other HMG-CoA reductase inhibitors
Toxic (necrosis) Hydrocarbon Carbon tetrachloride
Metal Yellow phosphorus
Mushroom Amanita phalloides
Analgesic Acetaminophen
Solvent Dimethylformamide
Granulomas Anti-inflammatory Phenylbutazone
Antibiotic Sulfonamides
Xanthine oxidase inhibitor
Allopurinol
Antiarrhythmic Quinidine
Anticonvulsant Carbamazepine
Cholestatic Reactions
Noninflammatory
22
Drug-induced cholestasis results from inhibition or genetic deficiency of various hepatobiliary
transporter systems. The following drugs cause cholestasis: anabolic steroids containing an alkyl or
ethinyl group at carbon 17, azathioprine, indinavir (increased risk of indirect hyperbilirubinemia in
patients with Gilbert syndrome), cyclosporine, estrogens, mercaptopurine, methyltestosterone, and
ticlopidine.
Inflammatory
The following drugs cause inflammation of portal areas with bile duct injury (cholangitis), often with
allergic features such as eosinophilia: amoxicillin-clavulanic acid (among most common causes of
drug-induced liver injury), azathioprine, azithromycin, captopril, cephalosporins, chlorothiazide,
chlorpromazine, chlorpropamide, erythromycin, mercaptopurine, penicillamine, prochlorperazine,
semisynthetic penicillins (eg, cloxacillin), and sulfadiazine. Cholestatic and mixed cholestatic
hepatocellular toxicity is more likely than pure hepatocellular to
xicity to lead to chronic liver disease.
Table 7. Idiosyncratic Drug Reactions and the Cells That Are Affected.4
Type of Reaction
Effect on Cells Examples of Drugs
Hepatocellular Direct effect or production by enzyme–drug adduct leads to cell dysfunction, membrane dysfunction, cytotoxic T-cell response
Isoniazid, trazodone, diclofenac, nefazodone, venlafaxine, lovastatin
Cholestasis Injury to canalicular membrane and transporters
Chlorpromazine, estrogen, erythromycin and its derivatives
Immunoallergic Enzyme–drug adducts on cell surface induce IgE response
Halothane, phenytoin, sulfamethoxazole
Granulomatous Macrophages, lymphocytes infiltrate hepatic lobule
Diltiazem, sulfa drugs, quinidine
Microvesicular fat
Altered mitochondrial respiration, oxidation leads to lactic acidosis and triglyceride accumulation
Didanosine, tetracycline, acetylsalicylic acid, valproic acid
Steatohepatitis Multifactorial Amiodarone, tamoxifen
23
Type of Reaction
Effect on Cells Examples of Drugs
Autoimmune Cytotoxic lymphocyte response directed at hepatocyte membrane components
Nitrofurantoin, methyldopa, lovastatin, minocycline
Fibrosis Activation of stellate cells Methotrexate, excess vitamin A
Vascular collapse
Causes ischemic or hypoxic injury Nicotinic acid, cocaine, methylenedioxymethamphetamine
Oncogenesis Encourages tumor formation Oral contraceptives, androgens
Mixed Cytoplasmic and canalicular injury, direct damage to bile ducts
Amoxicillin-clavulanate, carbamazepine, herbs, cyclosporine, methimazole, troglitazone
Table 8. Postulated Mechanisms of Drug-Induced Liver Disease.4
Effect Example
Alteration of the physical properties of membranes Estrogens
Inhibition of membrane enzymes (eg, Na+-K+ ATPase)
Chlorpromazine metabolites
Interference with hepatic uptake processes Rifampin
Impairment of cytoskeletal function Chlorpromazine metabolites
Formation of insoluble complexes in bile Chlorpromazine
Conversion to reactive intermediates
Electrophils producing covalent modifications of tissue macro-molecules
Acetaminophen
Free radicals producing lipid peroxidation Carbon tetrachloride
Redox cycling with production of oxygen radicals Nitrofurantoin
24
Acute or Chronic Hepatitis
Medications that may result in acute or chronic hepatitis that is histologically—and in some cases
clinically—indistinguishable from autoimmune hepatitis include aspirin, isoniazid (increased risk in
HBV and HCV carriers), methyldopa, minocycline, nitrofurantoin, nonsteroidal anti-inflammatory
drugs, and propylthiouracil. Hepatitis also can occur in patients taking cocaine,
methylenedioxymethamphetamine (MDMA; Ecstasy), efavirenz, imatinib mesylate, nevirapine
(increased risk in HBV and HCV carriers), ritonavir (greater rate than other protease inhibitors),
sulfonamides, telithromycin, troglitazone (withdrawn from the market in the United States), and
zafirlukast as well as a variety of alternative remedies (eg, chaparral, germander, jin bu huan, kava,
skullcap). In patients with jaundice due to drug-induced hepatitis, the mortality rate without liver
transplantation is at least 10%.
Other Reactions
Fatty Liver
Macrovesicular
This type of liver injury may be produced by alcohol, amiodarone, corticosteroids, methotrexate,
irinotecan, zalcitabine, and possibly oxaliplatin.
Microvesicular
Often resulting from mitochondrial injury, this condition is associated with didanosine, stavudine,
tetracyclines, valproic acid, and zidovudine.
Granulomas
Allopurinol, quinidine, quinine, phenylbutazone, and phenytoin can lead to granulomas.
Fibrosis and Cirrhosis
Methotrexate, and vitamin A are associated with fibrosis and cirrhosis.
Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease)
This disorder may result from treatment with antineoplastic agents (eg, pre-bone marrow transplant,
oxaliplatin), and pyrrolizidine alkaloids (eg, Comfrey).
Peliosis Hepatis (Blood-Filled Cavities)
25
Peliosis hepatitis may be caused by anabolic steroids and oral contraceptive steroids as well as
azathioprine and mercaptopurine, which may also cause nodular regenerative hyperplasia.
Neoplasms
Neoplasms may result from therapy with oral contraceptive steroids, including estrogens (hepatic
adenoma but not focal nodular hyperplasia); and vinyl chloride (angiosarcoma).7
Diagnosis
When a single agent is involved, the diagnosis may be relatively simple, but with multiple agents,
implicating a specific agent as the cause is difficult. To facilitate the diagnosis of drug-induced
hepatic injury, several clinical tools for causality assessment have been developed to assist the
clinician.
History: History must include dose, route of administration, duration, previous administration,
and use of any concomitant drugs, including over-the-counter medications and herbs.
Knowing whether the patient was exposed to the same drug before may be helpful. The
latency period of idiosyncratic drug reactions is highly variable; hence, obtaining a history of
every drug ingested in the past 3 months is essential.
o Onset: The onset is usually within 5-90 days of starting the drug.
o Exclusion of other causes of liver injury/cholestasis: Excluding other causes of liver
injury is essential.
Dechallenge: A positive dechallenge is a 50% fall in serum transaminase levels within 8 days
of stopping the drug. A positive dechallenge is very helpful in cases of use of multiple
medications.
Track record of the drug: Previously documented reactions to a drug aid in diagnosis.
Rechallenge: Deliberate rechallenge in clinical situations is unethical and should not be
attempted; however, inadvertent rechallenge in the past has provided valuable evidence that
the drug was indeed hepatotoxic.
Differential diagnoses
Acute viral hepatitis
Autoimmune hepatitis
26
Shock liver
Cholecystitis
Cholangitis
Budd-Chiari syndrome
Alcoholic liver disease
Cholestatic liver disease
Pregnancy-related conditions of liver
Malignancy
Wilson disease
Hemochromatosis
Coagulation disorders
Laboratory studies
Performing laboratory tests to assess and diagnose the effects of the suspected medication is essential.
These include complete blood cell count, basic metabolic profile, and urinalysis. Patients with a
hepatocellular process generally have a disproportionate elevation in serum aminotransferase levels
compared with alkaline phosphatase levels, while those with cholestasis have the opposite findings.
Hepatitis B serology (hepatitis B surface antigen, anti–hepatitis B surface antibody, anti–hepatitis B
core antibody, hepatitis C serology) and hepatitis A serology (anti–hepatitis A virus antibody) should
be performed to exclude an infectious etiology.
ANA testing may help in cases of possible autoimmune hepatitis. Positive ANA and ASMA findings
may add to the diagnostic evaluation but are usually confusing and hence not used. The presence of
antibodies to specific forms of CYP has been associated with hypersensitivity to some drugs. For
example, some antibodies and the associated drugs involved are as follows: CYP 1A2, dihydralazine;
CYP 3A1, anticonvulsants; and CPY 2E1, halothane. Their role in pathophysiology is uncertain but
may help in diagnosis. Lymphocyte transformation to test drugs may be observed for drugs acting
through immunologic reactions, but this is not commonly used.
Hepatic function tests and their interpretations are as follows:
Bilirubin (total) - To diagnose jaundice and assess severity
Bilirubin (unconjugated) - To assess for hemolysis
Alkaline phosphatase - To diagnose cholestasis and infiltrative disease
27
AST/serum glutamic oxaloacetic transaminase (SGOT) - To diagnose hepatocellular disease
and assess progression of disease
ALT/serum glutamate pyruvate transaminase (SGPT) - ALT relatively lower than AST in
persons with alcoholism
Albumin - To assess severity of liver injury (HIV infection and malnutrition may confound
this.)
Gamma globulin - Large elevations suggestive of autoimmune hepatitis, other typical increase
observed in persons with cirrhosis
Prothrombin time after vitamin K - To assess severity of liver disease
Antimitochondrial antibody - To diagnose primary biliary cirrhosis
ASMA - To diagnose primary sclerosing cholangitis
Imaging studies
Imaging studies are used to exclude causes of liver pathology, after which a diagnosis can be made.
Ultrasonography: Ultrasonography is inexpensive compared with CT scanning and MRI and
is performed in only a few minutes. Ultrasonography is effective to evaluate the gall bladder,
bile ducts, and hepatic tumors.
CT scanning: CT scanning can help detect focal hepatic lesions 1 cm or larger and some
diffuse conditions. It can also be used to visualize adjacent structures in the abdomen.
MRI: MRI provides excellent contrast resolution. It can be used to detect cysts,
hemangiomas, and primary and secondary tumors. The portal vein, hepatic veins, and biliary
tract can be visualized without contrast injections.
Procedures
Liver biopsy: Histopathologic evaluation remains an important tool in diagnosis. A liver
biopsy is not essential in every case, but a morphologic pattern consistent with the expected
pattern provides supportive evidence.
28
Treatment
Early recognition of drug-induced liver reactions is essential to minimizing injury. Monitoring hepatic
enzyme levels is appropriate and necessary with a number of agents, especially with those that lead to
overt injury. For drugs that produce liver injury unpredictably, biochemical monitoring is less useful.
ALT values are more specific than AST values. ALT values that are within the reference range at
baseline and rise 2- to 3-fold should lead to enhanced vigilance in terms of more frequent monitoring.
ALT values 4-5 times higher than the reference range should lead to prompt discontinuation of the
drug.
No specific treatment is indicated for drug-induced hepatic disease. Treatment is largely supportive
and based on symptomatology. The first step is to discontinue the suspected drug. Specific therapy
against drug-induced liver injury is limited to the use of N -acetylcysteine in the early phases of
acetaminophen toxicity. L-carnitine is potentially valuable in cases of valproate toxicity. In general,
corticosteroids have no definitive role in treatment. They may suppress the systemic features
associated with hypersensitivity or allergic reactions. Management of protracted drug-induced
cholestasis is similar to that for primary biliary cirrhosis. Cholestyramine may be used for alleviation
of pruritus. Ursodeoxycholic acid may be used. Lastly, consulting a hepatologist is also helpful.
Referral to liver transplantation center/surgical care
No specific antidote is available for the vast majority of hepatotoxic agents. Emergency liver
transplantation has increasing utility in the setting of drug-induced fulminant hepatic injury.
Considering early liver transplantation is important. The Model for End-Stage Liver Disease score can
be used to evaluate short-term survival in an adult with end-stage liver disease. This can help stratify
candidates for liver transplantation. The parameters used are serum creatinine, total bilirubin,
international normalized ratio, and the cause of the cirrhosis. Another criterion commonly used for
liver transplantation is the Kings College criteria.
Kings College criteria for liver transplantation in cases of acetaminophen toxicity are as
follows:
o pH less than 7.3 (irrespective of grade of encephalopathy)
o Prothrombin time (PT) greater than 100 seconds or international normalized ratio
greater than 7.7
29
o Serum creatinine level greater than 3.4 mg/dL in patients with grade III or IV
encephalopathy
Measurement of lactate levels at 4 and 12 hours also helps in early identification of patients
who require liver transplantation.
Kings College criteria for liver transplantation in other cases of drug-induced liver failure are
as follows:
o PT greater than 100 seconds (irrespective of grade of encephalopathy) or
o Any 3 of the following criteria:
Age younger than 10 years or older than 40 years
Etiology of non-A/non-B hepatitis, halothane hepatitis, or idiosyncratic drug
reactions
Duration of jaundice of more than 7 days before onset of encephalopathy
PT greater than 50 seconds
Serum bilirubin level greater than 17 mg/dL
Prognosis
The prognosis is highly variable depending on the patient's presentation and stage of liver damage. In
a prospective study conducted in the United States from 1998-2001, the overall survival rate of
patients (including those who received a liver transplant) was 72%. The outcome of acute liver failure
is determined by etiology, the degree of hepatic encephalopathy present upon admission, and
complications such as infections.2
30
References
1. Anthony SF, Eugene B, Dennis LK, et al. Harrison’s Manual of Medicine. McGraw-Hill
Professional. 2009; 11:757-72
2. Drug Induced Hepatitis. Saved from emedicine.medscape.com. June 2010
3. DeLeve LD, Kaplowitz N. Drug-Induced Liver Disease. Informa Health Care, 2007; 26:547-
66
4. Ganong WF, McPhee SJ. Pathophysiology of Disease. McGraw-Hill Professional. 2005; 13
5. Haist SA, Robbins JB, Gomella LG. Internal Medicine on Call, Lange Medical Book.
McGraw-Hill Professional. 2005; 255-9
6. Martin KJ, Schmitz PG. Internal Medicine : Just the Facts. McGraw-Hill Professional. 2008;
338-42
7. Papadakis MA, McPhee SJ. Current Medical Diagnosis and Treatment. McGraw-Hill
Professional. 2009; 16
31